AbbVie Reports Third-Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
AbbVie (ABBV) Tops Q3 EPS by 8c, Beats on Revenue; Offers FY25 EPS Guidance
October 31, 2025 7:50 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $1.86, $0.08 better than the analyst estimate of $1.78. Revenue for the quarter came in at $15.78 billion versus the consensus estimate of $15.58 billion.
GUIDANCE:
AbbVie sees FY2025 EPS of $10.61-$0.65, versus the consensus of $10.86.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More